SCHEMBL4335084

SCHEMBL4335084

Nc1cc(Oc2ccc(NC(=S)NC(=O)Cc3ccc(F)cc3)cc2)ccn1

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MET P08581 12/20 0.67
PDGFRA P16234 3/20 0.50
KIT P10721 1/20 0.50
AXL P30530 1/20 0.49
KMT2A Q03164 2/20 0.48
RAB9A P51151 1/20 0.47
CYP3A4 P08684 3/20 0.47
CSF1R P07333 2/20 0.45
PDGFRB P09619 2/20 0.45
FLT3 P36888 2/20 0.45
ALDH1A1 P00352 1/20 0.45
CYP1A2 P05177 1/20 0.45
MAPT P10636 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
KDR P35968 2/20 0.45
MEN1 O00255 1/20 0.44
GAA P10253 1/20 0.44
CDK8 P49336 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1137668 0.91 MET (0.80) METPDGFRACYP3A4CSF1RPDGFRB
SCHEMBL4329993 0.90 MET (0.61) METPDGFRAKITKMT2ARAB9A
SCHEMBL1137314 0.89 MET (0.83) METPDGFRAAXLCYP3A4CSF1R
SCHEMBL4324313 0.88 MET (0.62) METPDGFRAAXLKMT2ACYP3A4
SCHEMBL4335075 0.88 MET (0.53) METPDGFRAKITAXLKMT2A
SCHEMBL4323170 0.87 MET (0.69) METPDGFRAKITAXLCYP3A4
SCHEMBL1136788 0.86 SMN1; SMN2 (0.57) METPDGFRAKITAXLKMT2A
SCHEMBL14366187 0.85 MET (0.59) METPDGFRAKITKMT2ACSF1R
SCHEMBL4337508 0.84 MET (0.49) METPDGFRAKITAXLKMT2A
SCHEMBL13861002 0.81 MET (0.48) METPDGFRAKITAXLKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1719762-B1 NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (1) EISAI R&D MAN CO LTD (JP) 2012-06-27 EP claimed
EP-1719762-B1 NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (1) EISAI R&D MAN CO LTD (JP) 2012-06-27 EP disclosed
US-7531532-B2 Hepatocyte growth factor receptor inhibitors; Antitumor agents, anticarcinogenic agents, angiogenesis inhibitors; pyrimidine derivatives like Pyrrolidine-1-carboxylic acid [6-(2-fluoro-4-{3-[2-(4-fluorophenyl)acetyl]thioureido}phenoxy)pyrimidin-4-yl]amide EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-05-12 US disclosed
US-20070270421-A1 Novel pyridine Derivative and Pyrimidine Derivative (1) EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-11-22 US disclosed
EP-1719763-A1 NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (2) Eisai Co., Ltd. (JP) 2006-11-08 EP disclosed
EP-1719762-A1 NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (1) Eisai Co., Ltd. (JP) 2006-11-08 EP disclosed
US-20050277652-A1 Novel pyridine derivative and pyrimidine derivative EISAI CO., LTD. (JP) 2005-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070270421-A1 Novel pyridine Derivative and Pyrimidine Derivative (1) HGF, MET, FLT1 MET 2/4885PDGFRA 40/4885KIT 277/4885
US-20050277652-A1 Novel pyridine derivative and pyrimidine derivative HGF, MET, HDGF MET 2/4885PDGFRA 37/4885KIT 224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.